Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing

Soo Young Cho, Minhye Choi, Hyo Jeong Ban, Chang Hyeon Lee, Soojun Park, Han Kyeom Kim, Young Sik Kim, Young Seek Lee, Ji-Yun Lee

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Cervical small cell neuroendocrine tumors (CSCNETs) are rare, aggressive neuroendocrine tumors (NETs). Reliable diagnostic and prognostic CSCNET markers are lacking, making diagnosis and prognosis prediction difficult, and treatment strategies limited. Here we provide mutation profiles for five tumor-normal paired CSCNETs using whole exome sequencing (WES). We expanded our assessment of frequently mutated genes to include publicly available data from 55 small intestine neuroendocrine tumors, 10 pancreatic neuroendocrine tumors, 42 small cell lung cancers, six NET cell lines, and 188 cervical cancers, along with our five CSCNETs. We identified 1,968 somatic mutations, including 1,710 missense, 106 nonsense, 144 splice site, 4 lncRNA, 3 nonstop, and 1 start codon mutation. We assigned functions to the 114 most frequently mutated genes based on gene ontology. ATRX, ERBB4, and genes in the Akt/mTOR pathway were most frequently mutated. Positive cytoplasmic ERBB4 immunohistochemical staining was detected in all CSCNET tumors tested, but not in adjacent normal tissues. To our knowledge, this study is the first to utilize WES in matched CSCNET and normal tissues to identify somatic mutations. Further studies will improve our understanding of how ATRX and ERBB4 mutations and AKT/mTOR signaling promote CSCNET tumorigenesis, and may be leveraged in novel anti-cancer treatment strategies.

Original languageEnglish
Pages (from-to)8095-8104
Number of pages10
JournalOncotarget
Volume8
Issue number5
DOIs
Publication statusPublished - 2017

Fingerprint

Exome
Neuroendocrine Tumors
Mutation
Long Noncoding RNA
Genes
Neoplasms
Neuroendocrine Cells
Gene Ontology
Initiator Codon
Small Cell Lung Carcinoma
Tumor Biomarkers
Tumor Cell Line
Uterine Cervical Neoplasms
Small Intestine
Carcinogenesis

Keywords

  • AKT/mTOR
  • ATRX
  • Cervical small cell neuroendocrine tumor
  • ERBB4
  • Whole exome sequencing

ASJC Scopus subject areas

  • Oncology

Cite this

Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing. / Cho, Soo Young; Choi, Minhye; Ban, Hyo Jeong; Lee, Chang Hyeon; Park, Soojun; Kim, Han Kyeom; Kim, Young Sik; Lee, Young Seek; Lee, Ji-Yun.

In: Oncotarget, Vol. 8, No. 5, 2017, p. 8095-8104.

Research output: Contribution to journalArticle

Cho, Soo Young ; Choi, Minhye ; Ban, Hyo Jeong ; Lee, Chang Hyeon ; Park, Soojun ; Kim, Han Kyeom ; Kim, Young Sik ; Lee, Young Seek ; Lee, Ji-Yun. / Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing. In: Oncotarget. 2017 ; Vol. 8, No. 5. pp. 8095-8104.
@article{baa0ceca03404282acc697e025f0d074,
title = "Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing",
abstract = "Cervical small cell neuroendocrine tumors (CSCNETs) are rare, aggressive neuroendocrine tumors (NETs). Reliable diagnostic and prognostic CSCNET markers are lacking, making diagnosis and prognosis prediction difficult, and treatment strategies limited. Here we provide mutation profiles for five tumor-normal paired CSCNETs using whole exome sequencing (WES). We expanded our assessment of frequently mutated genes to include publicly available data from 55 small intestine neuroendocrine tumors, 10 pancreatic neuroendocrine tumors, 42 small cell lung cancers, six NET cell lines, and 188 cervical cancers, along with our five CSCNETs. We identified 1,968 somatic mutations, including 1,710 missense, 106 nonsense, 144 splice site, 4 lncRNA, 3 nonstop, and 1 start codon mutation. We assigned functions to the 114 most frequently mutated genes based on gene ontology. ATRX, ERBB4, and genes in the Akt/mTOR pathway were most frequently mutated. Positive cytoplasmic ERBB4 immunohistochemical staining was detected in all CSCNET tumors tested, but not in adjacent normal tissues. To our knowledge, this study is the first to utilize WES in matched CSCNET and normal tissues to identify somatic mutations. Further studies will improve our understanding of how ATRX and ERBB4 mutations and AKT/mTOR signaling promote CSCNET tumorigenesis, and may be leveraged in novel anti-cancer treatment strategies.",
keywords = "AKT/mTOR, ATRX, Cervical small cell neuroendocrine tumor, ERBB4, Whole exome sequencing",
author = "Cho, {Soo Young} and Minhye Choi and Ban, {Hyo Jeong} and Lee, {Chang Hyeon} and Soojun Park and Kim, {Han Kyeom} and Kim, {Young Sik} and Lee, {Young Seek} and Ji-Yun Lee",
year = "2017",
doi = "10.18632/oncotarget.14098",
language = "English",
volume = "8",
pages = "8095--8104",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "5",

}

TY - JOUR

T1 - Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing

AU - Cho, Soo Young

AU - Choi, Minhye

AU - Ban, Hyo Jeong

AU - Lee, Chang Hyeon

AU - Park, Soojun

AU - Kim, Han Kyeom

AU - Kim, Young Sik

AU - Lee, Young Seek

AU - Lee, Ji-Yun

PY - 2017

Y1 - 2017

N2 - Cervical small cell neuroendocrine tumors (CSCNETs) are rare, aggressive neuroendocrine tumors (NETs). Reliable diagnostic and prognostic CSCNET markers are lacking, making diagnosis and prognosis prediction difficult, and treatment strategies limited. Here we provide mutation profiles for five tumor-normal paired CSCNETs using whole exome sequencing (WES). We expanded our assessment of frequently mutated genes to include publicly available data from 55 small intestine neuroendocrine tumors, 10 pancreatic neuroendocrine tumors, 42 small cell lung cancers, six NET cell lines, and 188 cervical cancers, along with our five CSCNETs. We identified 1,968 somatic mutations, including 1,710 missense, 106 nonsense, 144 splice site, 4 lncRNA, 3 nonstop, and 1 start codon mutation. We assigned functions to the 114 most frequently mutated genes based on gene ontology. ATRX, ERBB4, and genes in the Akt/mTOR pathway were most frequently mutated. Positive cytoplasmic ERBB4 immunohistochemical staining was detected in all CSCNET tumors tested, but not in adjacent normal tissues. To our knowledge, this study is the first to utilize WES in matched CSCNET and normal tissues to identify somatic mutations. Further studies will improve our understanding of how ATRX and ERBB4 mutations and AKT/mTOR signaling promote CSCNET tumorigenesis, and may be leveraged in novel anti-cancer treatment strategies.

AB - Cervical small cell neuroendocrine tumors (CSCNETs) are rare, aggressive neuroendocrine tumors (NETs). Reliable diagnostic and prognostic CSCNET markers are lacking, making diagnosis and prognosis prediction difficult, and treatment strategies limited. Here we provide mutation profiles for five tumor-normal paired CSCNETs using whole exome sequencing (WES). We expanded our assessment of frequently mutated genes to include publicly available data from 55 small intestine neuroendocrine tumors, 10 pancreatic neuroendocrine tumors, 42 small cell lung cancers, six NET cell lines, and 188 cervical cancers, along with our five CSCNETs. We identified 1,968 somatic mutations, including 1,710 missense, 106 nonsense, 144 splice site, 4 lncRNA, 3 nonstop, and 1 start codon mutation. We assigned functions to the 114 most frequently mutated genes based on gene ontology. ATRX, ERBB4, and genes in the Akt/mTOR pathway were most frequently mutated. Positive cytoplasmic ERBB4 immunohistochemical staining was detected in all CSCNET tumors tested, but not in adjacent normal tissues. To our knowledge, this study is the first to utilize WES in matched CSCNET and normal tissues to identify somatic mutations. Further studies will improve our understanding of how ATRX and ERBB4 mutations and AKT/mTOR signaling promote CSCNET tumorigenesis, and may be leveraged in novel anti-cancer treatment strategies.

KW - AKT/mTOR

KW - ATRX

KW - Cervical small cell neuroendocrine tumor

KW - ERBB4

KW - Whole exome sequencing

UR - http://www.scopus.com/inward/record.url?scp=85018911358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018911358&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14098

DO - 10.18632/oncotarget.14098

M3 - Article

AN - SCOPUS:85018911358

VL - 8

SP - 8095

EP - 8104

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 5

ER -